Evidence map›Paper›PMID 36139781›Full record

ArticleAntioxidants (Basel, Switzerland)2022

Exploring the Formation of Polymers with Anti-Amyloid Properties within the 2'3'-Dihydroxyflavone Autoxidation Process.

Andrius Sakalauskas, Agne Janoniene, Gediminas Zvinys, Kamile Mikalauskaite, Mantas Ziaunys, Vytautas Smirnovas

Abstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Imidazo[2,1-ACS chemical neuroscience · 2024
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Andrius SakalauskasInstitute of Biotechnology, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.ORCID 0000-0002-2715-067X
Agne JanonieneInstitute of Biotechnology, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.
Gediminas ZvinysInstitute of Biotechnology, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.
Kamile MikalauskaiteInstitute of Biotechnology, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.
Mantas ZiaunysInstitute of Biotechnology, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.
Vytautas SmirnovasInstitute of Biotechnology, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.ORCID 0000-0002-1829-5455

Funding

European Commission 293476Lietuvos Mokslo Taryba VP1-3.1-ŠMM-07-K-02-020
6 · The paper itself

Abstract

Amyloid-β and α-synuclein aggregation into amyloid fibrils is linked to the onset and progression of Alzheimer's and Parkinson's diseases. While there are only a few disease-modifying drugs, it is essential to search for new, more effective ways to encounter these neurodegenerative diseases. Multiple research articles have shown that the autoxidation of flavone is a critical factor for activating the inhibitory potential against the protein aggregation. Despite this, the structure of the newly-formed inhibitors is unknown. In this research, we examined the autoxidation products of 2',3'-dihydroxyflavone that were previously shown to possess one of the most prominent inhibitory effects against amyloid-β aggregation. Their analysis using HPLC suggested the formation of polymeric molecules that were isolated using a 3 kDa cut-off. These polymeric structures were indicated as the most potent inhibitors based on protein aggregation kinetics and AFM studies. This revelation was confirmed using MALDI-TOF and NMR. We also show that active molecules have a tendency to reduce the Amyloid-β and α-synuclein aggregates toxicity to SH-SY5Y cells.

Indexed as

aggregationalpha-synucleinamyloid-betaautoxidationflavoneinhibitionpolymers

Identifiers

PMID36139781
PMCPMC9495709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.